CGON
NASDAQCG Oncology Inc.
$68.62-1.29 (-1.85%)
News25/Ratings12
Price$68.62-1.34 (-1.92%)
01:30 PM07:45 PM
News · 26 weeks45+150%
2025-10-262026-04-19
Mix1990d
- Insider9(47%)
- SEC Filings7(37%)
- Other3(16%)
Latest news
25 items- SECSEC Form DEFA14A filed by CG Oncology Inc.DEFA14A - CG Oncology, Inc. (0001991792) (Filer)
- SECSEC Form DEF 14A filed by CG Oncology Inc.DEF 14A - CG Oncology, Inc. (0001991792) (Filer)
- INSIDERSEC Form 4 filed by Mulay James4 - CG Oncology, Inc. (0001991792) (Issuer)
- SECSEC Form 144 filed by CG Oncology Inc.144 - CG Oncology, Inc. (0001991792) (Subject)
- INSIDERSEC Form 4 filed by Bellete Ambaw4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERSEC Form 4 filed by Kasturi Vijay4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERSEC Form 4 filed by Patterson Joshua F.4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERSEC Form 4 filed by Detore James M.4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERSEC Form 4 filed by Kuan Arthur4 - CG Oncology, Inc. (0001991792) (Issuer)
- SECCG Oncology Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - CG Oncology, Inc. (0001991792) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.SCHEDULE 13G/A - CG Oncology, Inc. (0001991792) (Subject)
- INSIDERDirector Mulay James sold $124,714 worth of shares (1,964 units at $63.50) and exercised 1,964 shares at a strike of $9.64 (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERChief Executive Officer Kuan Arthur covered exercise/tax liability with 1,847 shares and exercised 64,612 shares at a strike of $1.72, increasing direct ownership by 46% to 198,916 units (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERChief Executive Officer Kuan Arthur exercised 102,871 shares at a strike of $1.72 and covered exercise/tax liability with 2,871 shares, increasing direct ownership by 277% to 136,151 units (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- SECSEC Form S-8 filed by CG Oncology Inc.S-8 - CG Oncology, Inc. (0001991792) (Filer)
- SECSEC Form 10-K filed by CG Oncology Inc.10-K - CG Oncology, Inc. (0001991792) (Filer)
- SECCG Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CG Oncology, Inc. (0001991792) (Filer)
- PRCG Oncology Reports 2025 Year End Financial Results and Provides Business UpdatesPIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC expected first half 2026Well-positioned to deliver on key milestones with approximately $903.0 million cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2029 IRVINE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today reported financial results for the fourth quarter and year ended December 31, 2025, and provided business updates. "In the coming month
- PRCG Oncology to Present at the TD Cowen 46th Annual Health Care ConferenceIRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 3:10 pm ET. The conference is taking place at the Boston Marriott Copley Place in Boston, MA. Interested parties may access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available shortly after the conclusion of the live presentation and archived for approximately 90 days. About CG Onco
- PROncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead BiostatisticsSAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These appointments are expected to enhance the Company's operational, clinical, and regulatory capabilities as Oncolytics advances registration-directed development programs in pancreatic, colorectal, and anal cancers. Mr. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company's portfolio. He br
- SECSEC Form 8-K filed by CG Oncology Inc.8-K - CG Oncology, Inc. (0001991792) (Filer)
- SECSEC Form 424B5 filed by CG Oncology Inc.424B5 - CG Oncology, Inc. (0001991792) (Filer)
- INSIDERDirector Mulay James sold $584,799 worth of shares (11,145 units at $52.47) and exercised 11,145 shares at a strike of $12.07 (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- PRFast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 12, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The oncology landscape is entering a high-velocity regulatory phase as genomics in cancer care expands toward a projected $69.16 billion by 2032[1]. This massive growth is driven by the systematic integration of genotype-directed treatment pathways into standard medical practice. The precision medicine market is now on a trajectory to expand from $138.67 billion in 2026 to over $537.17 billion by 2035[2]. This strategic pivot toward registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), CG Oncology (NASDAQ:CGON), Ze
- SECSEC Form 144 filed by CG Oncology Inc.144 - CG Oncology, Inc. (0001991792) (Subject)